公司資料
Esperion Therapeutics 股價、新聞與催化劑
- 股票代碼:
- ESPR
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
3.18 USD (-0.31%)
收盤價
最後更新: 2026年7月10日
808M USD
市值
股價為何變動
Current closing-price context is not available for ESPR.
公司概覽
Oral Cardiometabolic Medicines
Esperion Therapeutics develops and commercializes oral therapies for cardiovascular risk reduction and is expanding toward rare hepatic and renal diseases. Its scientific foundation is inhibition of ATP citrate lyase.
Bempedoic Acid Franchise
NEXLETOL and NEXLIZET are once-daily, non-statin LDL-cholesterol-lowering medicines based on bempedoic acid. Esperion commercializes the products in the United States and works with partners across more than 40 countries.
Enbumyst Expansion
Esperion has agreed to acquire Corstasis Therapeutics and Enbumyst, an approved bumetanide nasal spray. The product would add a differentiated diuretic to its cardiovascular commercial portfolio.
Combination Development
The company is developing oral triple-combination regimens intended to deliver larger LDL-C reductions through complementary mechanisms. These products are designed to compete with other intensive lipid-lowering options while retaining oral administration.
Rare-Disease Pipeline
ESP-2001 is a wholly owned program for primary sclerosing cholangitis, a rare liver disease without approved treatment. Esperion is also applying its ACLY expertise to additional next-generation programs.
未來催化劑
- Canadian approval decision for NEXLIZET expected in 2026.
- Australian decisions on NEXLETOL and NEXLIZET expected in the fourth quarter of 2026.
- Completion of clinical requirements and planned commercialization of oral triple-combination products in 2027.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。